The State of Play

AI-driven screening and diagnosis across clinical imaging specialties — ophthalmology, dermatology, pathology, cardiology, and dental imaging — has cleared technical and regulatory bars and is now deployed across multiple institutions at scale. Diabetic retinopathy screening remains the leader: FDA-cleared autonomous systems exceed 90% sensitivity, and national programmes in Norway and the UK deploy at population scale. But the practice's centre of gravity is shifting: digital pathology has reached 57% adoption across research and clinical labs globally (2023 survey), with Roche's $750M acquisition of PathAI signaling ecosystem consolidation around major IVD players; multi-institutional deployments across colorectal and lung cancer cohorts now validate AI predictions of genetic mutations and immunotherapy response that rival molecular testing. Dermatology AI has achieved 100% melanoma sensitivity in collaboration workflows but surfaces critical equity barriers—a 7-point AUROC gap across skin tones (0.89 light vs. 0.82 dark skin). LLMs now exceed specialist-level accuracy on visual diagnosis tasks (ChatGPT 86.9% vs. pediatrician 46/61 on exanthems). The constraint has shifted from algorithm performance (which is proven) to systemic adoption: workflow integration, clinician oversight demand, algorithmic bias mitigation, and workforce skill gaps remain the primary blockers preventing rapid scaling despite technical maturity. Distinct from radiology AI in both imaging modalities and workflows, specialist clinical imaging sits at the boundary between leading-edge capability and vanguard implementation.

Ophthalmology (diabetic retinopathy screening remains most mature subspecialty): Three FDA-cleared autonomous platforms now dominate—EyeArt screens across 32 countries with EU MDR certification for three diseases and NHS deployment target; AEYE-DS integrates with Epic across 3,600+ US hospitals in sub-one-minute workflows; IDx-DR validates at 94.4% sensitivity (875-patient German cohort); Optomed Aurora AEYE now offers handheld autonomous screening (FDA June 2026) with <60-second results and subscription-based service model reducing capital barriers. Yet deployment-adoption divergence is stark: only 2.2% of imaged US diabetic patients received AI screening in 2024 despite FDA approvals and CPT reimbursement established since 2021. Real-world deployments show efficacy: Cary Medical Management (8 North Carolina clinics) achieved 15-20% HEDIS improvement and state-leading Medicare Shared Savings; Cleveland Clinic (multi-clinic) delivers 85-95% screening rates without dilation; Johns Hopkins demonstrates AI-assisted screening reduces racial disparities—African American patients 20.5 percentage-point higher referral rate via AI (64.9%) vs. PCP alone (44.4%), showing deployment-driven equity improvement. Multi-disease specialist screening now available: RetinAI's OCT Atlas (CE-marked for age-related macular degeneration, diabetic retinopathy, diabetic macular edema, glaucoma) demonstrates product-level ecosystem maturity; AI-OCT triage for macular edema achieves 45 percentage-point reduction in false-positive referrals (69%→24%) while maintaining diagnostic sensitivity, showing operational efficiency gains beyond diagnostic accuracy. Modality expansion emerging: smartphone-based AI for ocular malignancies now achieving 95% new-diagnosis rate on 614 real-world screenings via CaptureTumor mobile app (AUC 0.977), signaling specialty imaging extension beyond retinopathy. Yet systemic barriers persist: only 7.5% of ophthalmologists trust AI for diagnostics despite awareness; 83% of patients prefer physician involvement; 63.74% of healthcare professionals demand human-in-the-loop oversight; 41.23% cite workforce skill gaps as top barrier; 73% of NHS staff never use AI despite policy backing; 60% of US EHRs remain incompatible with third-party AI tools. Critical adoption constraint: 90% of health systems deployed AI imaging tools, but only 19% report genuine effectiveness; <15% of 1,200+ FDA-cleared medical AI devices see routine clinical use. Fundamental barriers documented: infrastructure/workflow integration determines success more than model performance (survey of 43 major US health systems); up to 81% of clinicians miss tools external to primary EHR workflows; explainability and trust remain unresolved (78% of FDA-cleared devices post-2019 lack explainability mechanisms). Reimbursement friction and workflow integration remain critical—nearly half of 150 health systems rated integration as 9-10 critical yet remained in limited deployment.

Pathology (emerging as second major deployment locus): Digital pathology adoption has reached 57% globally (2023 survey, 127 labs) with ~10% in US regulated labs. Enterprise-scale deployments now operational: PathAI's AISight Dx across MedStar Health's 40+ pathologist network; Aidoc processing 35,000 scans monthly across 28 European hospitals. Multi-institutional validation demonstrates maturity: Natera's AI trained on 45,000+ colorectal cancer patients achieves 98% MSI prediction and 93% BRAF mutation prediction from H&E alone; MD Anderson's Path-IO validated across 1,000+ patients predicts immunotherapy response; NCI/Harvard/Yale collaboration predicts immunotherapy response from routine slides without sequencing. Roche's $1.05B acquisition of PathAI (upgraded from $750M) consolidates ecosystem toward major IVD players, with autonomous reasoning systems (SPARK AI) now operating without human-in-the-loop for oncology diagnostics, signaling transition from research platform to mission-critical clinical infrastructure. Market projections estimate $2.07B market by 2032 (8.3% CAGR), driven by software/decision-support services and hospital adoption (46% revenue share). Multicentric benchmark (DALPHIN) confirms parity: foundation models (GPT-5, Gemini) and pathology-specific copilots (PathChat+) achieve specialist-level performance on 1-4 of 6 tasks across 31 pathologists, 14 subspecialties, 6 countries. However, pathology AI demonstrates the core leading-edge tension acutely: peer-reviewed analysis confirms "only a few AI systems have entered routine clinical practice" despite foundation/multimodal models achieving specialist-level performance. Critical barriers identified: data fragility (scanner shift, format fragmentation, manual QC), workflow misalignment (cognitive rhythm, automation bias, scenario-dependent latency), institutional trust gaps (interpretability, validation gaps, liability, generative AI risks). Cancer imaging AI faces validation gaps: scoping review of 371 explainable AI publications in radiologic cancer imaging found 50% lack validation, 321 lack clinical integration, reproducibility gaps endemic (only 65 share code; 280 do not).

Dermatology (deployment success with critical equity barriers): AI-enhanced CNNs achieve 100% melanoma sensitivity in collaboration workflows, with DermaSensor showing 96% sensitivity and 50% reduction in missed cancers in primary care. However, 2025 meta-analysis documents severe bias: AUROC 0.89 for light skin (Fitzpatrick I–III) vs. 0.82 dark skin (Fitzpatrick IV–VI), with one model dropping to 0.57 on dark skin and 0.50 (random) on darkest tones. This equity gap reflects dataset composition bias and represents critical barrier to equitable population-scale deployment despite algorithm maturity.

Emerging vision-language capability (LLMs exceed specialist accuracy): ChatGPT (86.9%) and Gemini (82.0%) exceeded 263 specialist pediatricians (median 46/61) on visual diagnosis of childhood rashes with clinical data, signalling emergence of multimodal AI as diagnostic peer to human specialists across imaging domains. Oculomics advancing specialist imaging scope: Reti-Pioneer (107K images, 6 endocrine/metabolic diseases) and RETFound (752 diseases, 61K UK Biobank participants) demonstrate retinal imaging as multimodal decision layer for systemic disease prediction with real-world deployment success rates (98.7% image acquisition, 100% inference success in prospective pilots), enabling rapid screening workflows that previously required 8+ hours laboratory time. Adoption remains constrained by same barriers across all specialties: algorithmic bias across demographics (7-point AUROC gap in dermatology AI across skin tones), workflow integration challenges requiring moment-of-decision alignment, clinician oversight demand and trust deficits, and workforce skill gaps—with real-world implementation barriers (legacy EHR incompatibility, change management friction, clinician readiness gaps) dominating the landscape more than technical capability gaps. Real-world primary care validation in New Zealand documented barriers: legacy hospital software incompatibility, model-of-care misalignment, algorithmic bias risks across demographic variation. Pilot-to-scale failure documented across health systems: 70%+ AI pilot failures driven by execution and change management gaps, not technology limitations.

• 2016: Deep learning drives accuracy improvements in diabetic retinopathy screening (96.8% sensitivity achieved). Independent NHS validation confirms real-world performance on 20,258 patients. EyeArt 2.0 launches commercially in Europe with 91% sensitivity. Clinical implementation studies reveal workflow integration barriers (47% agreement in routine care). Training data quality and annotation consistency emerge as core technical challenges.
• 2017: Large-scale validation continues—independent study across 20,258 patients confirms EyeArt, Retmarker, and iGradingM all achieve 94.7%–99.6% sensitivity with cost-effectiveness. Real-world deployment expands: Los Angeles County safety-net system operates full-scale teleretinal DR screening, reducing wait times from ≥8 months. Small pilot deployments (Oslo, 64 eyes) show 100% AI-human concordance and cost savings. FDA regulatory pathway for digital pathology devices approved, but guidance on autonomous AI in clinical decision support remains unclear, creating adoption uncertainty.
• 2018: Regulatory inflection: IDx-DR becomes first FDA-approved autonomous AI system for diabetic retinopathy screening in primary care (April 2018). Clinical validation accelerates with prospective multicenter studies in US (87% sensitivity), Netherlands (91% sensitivity), and China, demonstrating geographic generalization. Competitive landscape solidifies with multiple FDA-cleared platforms (EyeArt, Retmarker, iGradingM, AEYE Health). Critical voices emerge questioning safety rigor and clinical outcome evidence. Reimbursement and workflow integration barriers become adoption blockers despite regulatory approval.
• 2019: Global scale-up of real-world deployments: EyeArt system deployed across 404 primary care clinics on 101,710 consecutive patient visits demonstrates real-world sensitivity of 91.3% and 98.5% for treatable DR. Lancet Digital Health meta-analysis confirms diagnostic performance of deep learning equivalent to healthcare professionals across medical imaging modalities. Geographic expansion continues—IDx-DR integrated into Vienna General Hospital and MedUni Vienna clinical workflows with near-perfect accuracy. Deployment now spans five continents with 500,000+ patient visits. Critical assessment literature questions readiness of widespread adoption despite technological validation, emphasizing gaps between algorithm accuracy and clinical workflow integration.
• 2020: Consolidation of clinical deployment at scale. Large-scale validation in English Diabetic Eye Screening Programme (30,000 patients, 120,000 images) confirms EyeArt 95.7% accuracy with 100% sensitivity for severe DR and £10M annual cost-savings potential. EyeArt receives FDA 510(k) clearance with 96% sensitivity for more than mild DR. Clinical adoption remains constrained by reimbursement friction (unclear billing codes in US) and workflow integration challenges despite demonstrated safety and cost-effectiveness. Deployment continues to concentrate in well-resourced health systems and developed markets.
• 2021: Peer-reviewed validation of EyeArt pivotal trial in JAMA Network Open (942 patients, 96% sensitivity for more-than-mild DR) strengthens evidence base. Medicare begins reimbursing autonomous DR screening in January, yet adoption barriers persist: workflow integration challenges, cost considerations, and limited patient acceptance. Industry analysis identifies four core adoption blockers—ecosystem interoperability gaps, data biases, regulatory uncertainty, and ROI concerns—highlighting that technical capability alone does not drive clinical scaling.
• 2022-H1: Regulatory consolidation accelerates with UK National Screening Committee declaring EyeArt "only technology ready for live NHS implementation" (June). Real-world deployment expands geographically—portable smartphone-based systems achieve 97.8% sensitivity in Brazil; Google validates ultra-widefield AI with 90.5% sensitivity; Vienna medical center confirms IDx-DR accuracy in routine clinical practice. However, deployment diversity reveals algorithm generalization challenges: Chinese multicenter study documents only 33.9% sensitivity for vision-threatening DR despite 78.97% for referral-level disease. Systematic methodological review exposes research biases (data quality, publication incentives, inadequate clinical assessment) in the medical imaging AI field, reinforcing gap between algorithm validation and real-world implementation maturity.
• 2022-H2: Peer-reviewed evidence strengthens: EyeArt clinical study shows 96.4% sensitivity vs. 27.7% for ophthalmologists on 521 patients; Chinese AI-based DR grading achieves 96.5% accuracy and improves junior resident training. Deployment extends into underserved markets—EyeArt now screening remote Ontario Indigenous communities (2,700 patients, autonomous results in <30 seconds). Critical assessment literature surfaces persistent adoption barriers: implementation reviews identify data governance, algorithm robustness, ethics, and regulatory clarity as blockers despite technical maturity; field-wide research biases and inadequate clinical outcome assessment inflate confidence in algorithm performance. Algorithm generalization remains the core fault line: systems validated on curated datasets show materially lower performance on severe pathology and different populations.
• 2023-H1: Regulatory expansion consolidates: EyeArt achieves EU MDR Class IIb certification for diabetic retinopathy, age-related macular degeneration, and glaucoma (first system with three-disease scope); EyeArt 2.2.0 receives FDA clearance for multi-camera support (Canon + Topcon). Real-world deployment continues: UMass Memorial Health launches 500-patient pilot with AEYE Health's handheld AI camera in primary care; Frontiers study identifies workflow determinants for sustainable IDx-DR adoption (95% volume growth with clinical champions and resource alignment). Clinical validation pipelines mature: AEYE-DS enters pivotal trials; FDA publishes regulatory frameworks for medical imaging AI. Field consolidation accelerates around mature platforms (EyeArt, IDx-DR) with incremental regulatory expansion. Implementation research confirms regulatory approval no longer bottlenecks adoption—workflow integration, clinical champions, and algorithmic robustness remain primary constraints.
• 2023-H2: Commercial partnerships expand ecosystem: IRIS platform (600+ clinics and labs) integrates AEYE Health's autonomous DR detection system. Research and critical assessment literature quantifies persistent adoption barriers: December study across five UC health systems identifies systemic obstacles to DR screening program implementation; concurrent literature documents slow adoption despite algorithm effectiveness. Regulatory framework guidance from FDA continues to mature. Consolidation accelerates around mature platforms (EyeArt, IDx-DR, AEYE-DS) with emphasis on clinical partnership and workflow integration rather than further algorithm improvements. Adoption bottleneck remains institutional: implementation barriers, resource allocation, and clinical champion engagement dominate over technical validation.
• 2024-Q1: Real-world deployments expand: Nebraska Medicine begins testing EyeArt in two primary care clinics with 28% referral rate; Tarzana Treatment Centers reports similar adoption with ~25% detection on 700 annual exams. Digital Diagnostics' platform reaches ~600 sites nationwide. Implementation research broadens geographic scope: studies address DR screening effectiveness in high-resource settings (Japan) and low-resource contexts (sub-Saharan Africa). AEYE-DS enters formal clinical validation (NCT06241664, 500 participants). Reimbursement remains a constraint: CMS rate of $45.36 per autonomous screening does not offset equipment and integration costs. Adoption continues steady growth through clinical partnerships rather than explosive market expansion; barriers (EHR integration, staff training, algorithm generalization) persist despite proven technology maturity.
• 2024-Q2: AEYE-DS achieves FDA clearance (April) as first fully autonomous portable AI for DR screening, expanding ecosystem diversity. Clinical deployments consolidate at named health systems: Barnstable Brown Diabetes Center (UK HealthCare, Kentucky) reports 22,000 annual screenings; cost-analysis in Oslo (Norway) validates 100% sensitivity in minority women with $143/patient savings. Critical research surfaces adoption barriers: MIT study (June) identifies bias mechanisms in medical imaging AI models across demographic groups; peer-reviewed analyses highlight clinician ambivalence and clinical translation gaps as primary inhibitors despite regulatory approval. No AI medical tool yet incorporated into clinical guidelines as established practice norm. Adoption remains constrained by systemic barriers (workflow integration, cost justification, algorithmic fairness) rather than algorithm performance alone.
• 2024-Q3: Clinical deployments continue geographic expansion with fresh real-world outcome evidence. Johns Hopkins Medicine implementation research demonstrates improved adherence to annual testing with autonomous AI systems. UPMC's decade-long telemedicine program study (21,960 exams) documents sustainable deployment model with 31.5% specialist referral rates. Mary Lanning Healthcare reports 39% rise in screening adherence and 300,000+ cumulative patients screened. Internationally, EyRIS secures national government contract (Brunei, September 2024) for rollout across 40,000 diabetic citizens, signaling public health system adoption at scale. Scoping reviews synthesize persistent barriers: governance gaps, trust mechanisms, and clinical translation gaps continue to limit scaled adoption despite proven efficacy. Research confirms DR screening AI remains mature on algorithm performance but faces unresolved systemic barriers (workflow integration, regulatory clarity, equity concerns) constraining rapid health system scaling.
• 2024-Q4: Regulatory milestone achieved: AEYE Health's AEYE-DS becomes first fully autonomous portable AI system cleared by FDA (November 2024) with 92–93% sensitivity and single-image success rates >99%, expanding access beyond fixed-camera settings. Real-world deployments consolidate: Eyenuk's EyeArt integrated into Henrietta Johnson Medical Center (Delaware FQHC, October) with 26% positive DR detection; ecosystem now spans 32 countries with annual screening volumes exceeding 500,000 in rural India alone. However, critical adoption research (November, JAMA Ophthalmology) reveals fundamental gap: only 2.2% of imaged diabetic patients received AI-based screening despite FDA approvals, indicating nascent real-world penetration. Market analysis highlights structural barriers: VC funding for medical imaging AI collapsed (from $1.1B peak in 2021 to $207.5M in Q1–Q3 2024); 60% of US primary care EHRs remain incompatible with third-party AI tools. Despite technological maturity and regulatory approval, systemic adoption blockers (reimbursement, EHR integration, clinician adoption) persist at end of 2024.
• 2025-Q1: Real-world deployments continue: Johns Hopkins Medicine case study demonstrates improved access and equity through autonomous AI systems in both pediatric and adult populations. Multi-system quality improvement program deploys 198 AI cameras across 5 health systems, screening 20,000+ patients with diabetic retinopathy detection in 3,450+ cases. New portable technologies advance: AI Optics receives FDA 510(k) clearance for non-dilated handheld Sentinel Camera, enabling point-of-care screening beyond fixed-office settings. Critical research emphasizes systemic barriers: comprehensive review of bias in medical imaging AI identifies fundamental challenges to equitable deployment across demographics; Digital Pathology Association highlights risks of over-reliance on AI and need for human oversight in specialist diagnosis (pathology, dermatology). Survey of US pathologists documents widespread barriers to digital pathology adoption, mirroring ophthalmology challenges. Evidence accumulates that technical validation and regulatory clearance remain insufficient drivers of scaled clinical implementation; equity concerns, bias mitigation, and workflow integration persist as primary adoption constraints.
• 2025-Q2: Geographic expansion continues: Eyenuk's EyeArt deployed at Diabetes Center Mergentheim in Germany, establishing first dedicated diabetic clinic in Germany using autonomous AI screening. Commercial ecosystem consolidates: BeamMed announces partnership to promote AEYE-DS through subscription model, targeting broader primary care penetration. UK National Screening Committee publishes evidence review for implementing machine learning autograders in diabetic eye screening programs, highlighting adoption considerations for national health systems. Ecosystem now spans 32 countries with multi-system deployments exceeding 20,000+ annual screenings in US health systems and 500,000+ in rural India. However, systemic barriers (EHR integration, bias mitigation, national policy adoption) continue to constrain rapid scaling despite technical maturity and regulatory approval.
• 2025-Q3: National health system adoption reaches watershed moment: South-Eastern Norway Regional Health Authority (3.1M population) deploys EyeArt for autonomous DR screening with target to increase coverage from 55% to 95%. Italy completes first national prevention campaign, screening 2,200 patients across 30 centers with 214 new referable DR diagnoses. Real-world implementation in India documents variable performance (60–80% sensitivity), revealing algorithm generalization challenges in low-resource settings. FDA data (September 2025) surfaces quality assurance concerns: only 2.4% of 1,016 authorized AI medical devices had RCT support, 24.1% had no clinical studies, 4.8% recalled within 1.2 years. Ecosystem maturity marked by proven deployment but persistent systemic barriers: algorithm fairness, evidence quality, and health system integration remain core constraints to rapid global scaling.
• 2025-Q4: Peer-reviewed research confirms algorithm superiority (EyeArt 96.4% sensitivity vs. 27.7% for ophthalmologists) while cross-national ophthalmologist survey reveals adoption gap (only 7.2% regular use despite 69.5% perceiving potential). Independent UK validation (1,257 NDESP patients) shows 92–100% EyeArt sensitivities with 50–67% workload reduction potential. IRIS partnership integrates AEYE-DS across 600+ primary care clinics, expanding ecosystem access. End-user research surfaces fundamental adoption blockers: demand for robust evidence of effectiveness and maintained human oversight indicate algorithm maturity alone insufficient for scaled clinical implementation. Systemic barriers (EHR incompatibility, bias mitigation, fair pricing) persist despite regulatory clearances and demonstrated technical performance.
• 2026-Jan: AEYE-DS receives FDA 510(k) clearance (January 2); UK National Screening Committee selects EyeArt as only AI ready for NHS live implementation (January 25). Meta-analysis confirms EyeArt diagnostic accuracy across 17 studies (AUC 0.932). University of Utah Health deploys deepeye TPS for AMD treatment planning in Europe; US trial discussions ongoing. Epic EMR integration expands AEYE-DS deployment across US health system. Critical legal analysis surfaces regulatory compliance barriers (Anti-Kickback, False Claims Act risks) alongside technical maturity.
• 2026-Feb: Real-world validation confirms deployment maturity but reveals adoption divergence. IDx-DR shows 94.4% sensitivity in German real-world cohort (875 patients). AEYE-DS Epic integration reaches 3,600+ US hospitals enabling sub-one-minute autonomous screening. Patient satisfaction high (92% at Johns Hopkins) but 83% prefer physician oversight. Clinician trust remains low—Bulgarian survey of 156 ophthalmologists shows only 7.5% trust AI for diagnosis despite awareness. Analyst research confirms workflow integration critical but nearly half of organizations stuck in limited deployment despite algorithm maturity.
• 2026-Q1: Specialist imaging AI demonstrates continued real-world deployment with mixed outcomes. Primary care network (Cary Medical Management, North Carolina) deployed Optomed Aurora AEYE across 8 clinics showing dramatic clinical impact—one in three patients scanned revealed retinal changes requiring specialist referral; HEDIS quality metrics improved 15-20% and achieved highest Medicare Shared Savings performance in state through early detection and workflow integration without physician confidence-building requirements. Cleveland Clinic deployed AI-powered nonmydriatic fundus cameras across multiple clinic types (eye institute, primary care, endocrinology), delivering 30-second results with 85-95% screening rates without dilation and immediate EMR integration. Multi-pathology deployment evidence emerges: UPRETINA system validated across 1,652 eyes in teleophthalmology workflow with DR 86.8%/95.6%, AMD 94.9%/94.3%, glaucoma 82.7%/92.4% sensitivity/specificity, and Erasmus Hospital endocrinology deployment achieved 100% sensitivity on vision-threatening DR across diverse demographic groups. AEYE-DS Epic integration expanded to dozens of hospitals nationwide with 1-minute autonomous screening workflow and full CPT 92229 reimbursement support. Evidence on adoption barriers deepens: groundy.com analysis documents performance-deployment paradox (LumineticsCore 95% sensitivity yet only ~10% US hospitals have clinical AI adoption); multinational survey (2026) finds 63.74% of healthcare professionals demand human-in-the-loop oversight; India-focused primary research shows 23.39% institutional adoption rate despite 60% awareness, with 41.23% citing workforce skill gaps as top barrier. Practice scope expansion signals: FDA breakthrough designation for CLAiR enables cardiovascular risk screening via retinal imaging (91.1% sensitivity/86.2% specificity in 874-person prospective cohort), demonstrating specialist imaging AI moving beyond ophthalmology into systemic disease detection.
• 2026-Apr: Deployment evidence deepened across primary care and specialty settings: Cary Medical Management's 8-clinic North Carolina deployment and Cleveland Clinic's multi-site implementation each confirmed 85-95% screening rates and immediate EMR integration without requiring physician confidence-building. Erasmus Hospital's endocrinology deployment achieved 100% sensitivity on vision-threatening DR across diverse demographics. The adoption-performance gap remained stark: a survey of 342 healthcare professionals found 63.74% demanding human-in-the-loop oversight and 41.23% citing workforce skill gaps as the top barrier, while only 23.39% of institutions had adopted diagnostic AI despite 60% awareness. CLAiR's ACC 2026 presentation confirmed cardiovascular risk screening via retinal imaging (91.1% sensitivity, 86.2% specificity in 874-person prospective cohort), reinforcing the trend toward multi-disease specialist screening platforms.
• 2026-May: Enterprise-scale pathology deployment advanced with PathAI's FDA-cleared AISight Dx platform rolling out across MedStar Health's 40+ pathologist network, and Aidoc processing 35,000 scans monthly across 28 European hospitals — signalling operator-level adoption beyond ophthalmology. Roche's $750M PathAI acquisition consolidated ecosystem around major IVD players; SPARK AI now operates autonomous oncology diagnostics without human-in-the-loop; AACR 2026 presentations validated multi-institutional deployments at scale (Natera 45,000+ patients, 98% MSI prediction; NCI/Harvard/Yale predicting immunotherapy response from H&E slides). DALPHIN multicentric benchmark (31 pathologists, 10 countries, 14 subspecialties) confirmed PathChat+ achieves specialist parity on 4 of 6 tasks. Dermatology equity barriers sharpened: AUROC gap of 7 points across skin tones (0.89 light vs. 0.82 dark skin) and as low as 0.57 on darkest tones despite 96% overall sensitivity — a documented systemic barrier to equitable population-scale deployment. Vision-language models crossed a new threshold: ChatGPT (86.9%) and Gemini (82.0%) exceeded 263 specialist pediatricians on visual diagnosis of childhood exanthems, signalling multimodal AI approaching diagnostic peer status. Digital pathology market projected to exceed $2B by 2032 with 57% global lab adoption already recorded. Physician commentary raised sustainability concerns about the human-in-the-loop model as AI capabilities advance past subspecialist-level accuracy.
• 2026-Jun: Roche completed a $1.05B PathAI acquisition (up from earlier $750M reporting), consolidating digital pathology into major IVD infrastructure and signaling the practice's transition from research platform to mission-critical clinical asset. Specialist-model advances confirmed: CMR-CLIP cardiac foundation model (13,000+ patient studies) outperforms general-purpose AI by 35% with 99% accuracy on specific cardiac conditions, while Path-IO pathomics across MD Anderson, Mayo, and Gustave Roussy (797 patients) demonstrates superior prognostic performance (C-index 0.69 OS vs. 0.58 for FDA-standard PD-L1), moving specialist imaging from detection into prognosis. Modality expansion advanced: smartphone-based AI (CaptureTumor, JAMA Ophthalmology) achieved AUC 0.977 on ocular malignancy screening across 614 real-world cases with 95% new-diagnosis rate, signaling specialty imaging extending beyond retinopathy; RetinAI OCT Atlas received CE marking for four indications (AMD, DR, DME, glaucoma) with 1M+ patient images and 40+ CE marks, demonstrating multi-indication ecosystem maturity. AI-OCT triage for DME achieved a 45 percentage-point absolute reduction in false-positive referrals (69%→24%) while maintaining 100% sensitivity, confirming operational efficiency gains beyond diagnostic accuracy. Equity evidence strengthened on both sides: Johns Hopkins real-world deployment documented African American patients receiving a 20.5 percentage-point higher referral rate via AI (64.9%) vs. PCP alone (44.4%), demonstrating deployment-driven disparity reduction; Madhunetra government program deployed AI diabetic retinopathy screening across 45 medical colleges in 12 Indian states targeting 9,000 screenings, demonstrating public-health sector scale. Optomed Aurora AEYE received FDA clearance for handheld autonomous DR screening (<60 seconds per eye) with subscription-based model, further lowering capital barriers to point-of-care retinal screening. Critical deployment-reality barriers hardened: a Stanford-Harvard ARISE audit found 1,200+ FDA-cleared AI medical devices exist but fewer than 15% see routine clinical use—deployment curve has decoupled from validation curve; NHS analysis revealed 73% of UK healthcare professionals have never used AI despite 76% supporting it in principle; peer-reviewed analysis documents 20-35 point accuracy degradation from benchmark to live EHR, with systematic underperformance on Black patients, females under 50, and comorbid populations. Workflow-integration failure documented as primary adoption constraint: analysis of 43 major US health systems found 90% deployed imaging AI but only 19% report genuine effectiveness, with up to 81% of clinicians missing tools external to their primary EHR workflow; New Zealand 18-month primary care pilot documented legacy software incompatibility, care-model misalignment, and clinician readiness gaps as deployment barriers beyond algorithm maturity. XAI requirements emerged as structural barrier: 78% of FDA-cleared AI devices approved post-2019 lack explainability mechanisms, with saliency maps failing reliable localisation—documenting explainability and governance infrastructure as critical adoption prerequisites. Pathology AI adoption paradox confirmed peer-reviewed: algorithms advanced, clinical integration minimal—only a few systems entered routine practice despite specialist-level benchmark performance, with data fragility, workflow misalignment, and institutional trust gaps as primary constraints. Healthcare organizations face a triple cost structure (AI + human reviewer + IT infrastructure) where regulatory sign-off requirements eliminate expected savings, and JAMA Ophthalmology identifies that oculomics models reaching expert-level technical performance on dementia and stroke detection lack proof of clinical utility improvement—a gap between algorithm readiness and adoptable clinical practice.